StockWatch
·

Parmax Pharma Ltd Q3 FY26 Results

PARMAXQ3 FY26 Results
Filing
MetricValue ( Cr)Q2 FY26Q3 FY25
Revenue4.3370.9%31.2%
Total Income4.3370.7%31.2%
Expenditure5.069.7%24.3%
PBT-0.7364.8%85.3%
Net Profit-0.7364.8%85.3%
OPM-4.56%58.25pp10.13pp
NPM-16.89%65.01pp10.62pp
EPS1.9664.8%286.7%
View full financials

Informational and educational content only. Not investment advice.